A Randomized Phase II Trial Evaluation of the Addition of the Pediatric Cancer Resource Equity (PediCARE) Health Equity Intervention to Usual Supportive Care for Children With Newly Diagnosed High-Risk Neuroblastoma
A Randomized Phase II Trial Evaluation of the Addition of the Pediatric Cancer Resource Equity (PediCARE) Health Equity Intervention to Usual Supportive Care for Children With Newly Diagnosed High-Risk Neuroblastoma
This is a randomized Phase II trial evaluating the addition of the Pediatric Cancer Resource Equity (PediCARE) health equity intervention to usual supportive care for poverty-exposed children with newly diagnosed high-risk neuroblastoma.
The names of the intervention groups in this research study are:
This is a randomized Phase II trial evaluating the addition of the Pediatric Cancer Resource Equity (PediCARE) health equity intervention to usual supportive care for poverty-exposed children with newly diagnosed high-risk neuroblastoma.
Participants will be randomized into one of two groups: Usual Supportive Care vs. PediCARE + Usual Supportive Care. Randomization means a participant is placed into a group by chance.
Participation in this research study is expected to last 6-months.
It is expected about 130 people will participate in this research study.
Inclusion Criteria:
Patient must have a new diagnosis of high-risk neuroblastoma.
Patient must be enrolled on APEC14B1 and must have consented to future contact on APEC14B1.
Patient must be enrolled on ANBL2131.
Patient aged 0-17 years at the time of consent to ANBL2131.
Patient must have opted-in to embedded optional ANBL2131 Household Survey.
Family screened positive for HMH or low-income on ANBL2131 Household Survey. *
Patient has not yet initiated Induction Cycle 3 on ANBL2131.
Patient being treated at a U.S. site.
Patients of all languages are eligible to participate.
Exclusion Criteria:
-Patient has transferred to ANBL1531 Arm E.